CIRM Clinical Trials

Through its strategic funding of clinical trials, CIRM helps advance innovative stem cell and gene therapy discoveries toward future treatments for patients.

CIRM funds clinical trials across a broad range of diseases and conditions that include rare and genetic disorders, treatment-resistant and refractory diseases, and many forms of cancer. Our involvement in the clinical trial process is vital to transforming potential treatments into available therapies by accelerating pathways to commercialization. Visit our Funding Opportunities page to apply for clinical trial research funding.

0

CIRM-Funded Clinical Trials

Disease AreasInvestigatorOrganizationPhaseTrial StatusTarget EnrollmentDetail
Sickle Cell Disease Dr. De-Fu Zeng City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 3
HIV/AIDS Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 12
COVID-19
Respiratory Disorders		 Prof. John A. Zaia City of Hope, Beckman Research Institute Phase 1 Launching N/A
Bladder or Urinary Tract Disorder James Yoo Wake Forest University Health Sciences Phase 1 Not yet recruiting 10
Heart failure Dr. Joseph C. Wu Stanford University Phase 1 Recruiting 18
Leukemia, Acute Myeloid (AML) Joseph Paul Woodard Immune-Onc Therapeutics Phase 1 Recruiting 106
Parkinson's Disease Dr. Edward Wirth III Aspen Neuroscience Phase 1 Launching N/A
Sickle Cell Disease David Williams Boston Children’s Hospital Phase 2 Recruiting 25
Huntington's Disease Dr. Vicki Wheelock University of California, Davis Phase 1/2 Completed 29
Blood Cancer
Solid Tumors		 Professor Irving L Weissman MD Stanford University Phase 1 Completed 88
Solid Tumors Pei Wang Eureka Therapeutics, Inc. Phase 1/2 Launching N/A
Brain Cancer Dr. Leo D Wang City of Hope, Beckman Research Institute Phase 1 Recruiting 18
Sickle Cell Disease Mark C. Walters M.D. University of California, San Francisco Phase 1 Not yet recruiting 9
Kidney Disease Dr. Jeffrey L Veale University of California, Los Angeles Phase 1/2 Launching N/A
COVID-19
Respiratory Disorders		 William van der Touw Celularity Inc. Phase 1/2 Closed 86
Brain Cancer Dr. Reena Parada Thomas Stanford University Phase 1 Launching N/A
HIV/AIDS Geoff Symonds Calimmune, Inc. Phase 1/2 Completed 13
Amyotrophic Lateral Sclerosis Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1/2 Completed 18
Retinitis Pigmentosa Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1 Recruiting 16
Amyotrophic Lateral Sclerosis Professor Clive Niels Svendsen Cedars-Sinai Medical Center Phase 1 Launching N/A
Type 1 diabetes Peter Stock University of California, San Francisco Phase 1/2 Recruiting 8
Age-related macular degeneration Dr. Jeffrey H Stern Luxa Biotechnology Phase 1/2 Launching N/A
Stroke Dr. Gary Steinberg Stanford University Phase 1 Recruiting 30
Heart failure Dr. Rachel Ruckdeschel Smith Capricor, Inc Phase 2 Closed 135
Solid Tumors Dr. Dennis J Slamon University of California, Los Angeles Phase 1 Completed 46
Type 1 diabetes Dr. William Sietsema Caladrius Biosciences Phase 2 Completed 113
Danon Disease
Pediatrics		 Dr. Jonathan Schwartz Rocket Pharmaceuticals, Inc. Phase 2 Launching N/A
Lupus, Systemic Lupus Erythematosus (SLE) Dr. Vaneet Sandhu Fate Therapeutics, Inc. Phase 1 Launching N/A
Immune Disease Dr. Maria Grazia Roncarolo Tr1X Inc. Phase 1 Launching N/A
Melanoma
Skin cancer		 Dr. Antoni Ribas MD/PhD University of California, Los Angeles Phase 1 Closed 5
Bone or Cartilage Disease Dr. Gayatri Rao Rocket Pharmaceuticals, Inc. Phase 1 Closed 1
Blood Disorders Ilya Rachman MD PhD Nexcella, Inc. Phase 1 Launching N/A
Bone Marrow Transplant and Viral Infection Michael A. Pulsipher Children’s Hospital of Los Angeles Phase 1/2 Active, not recruiting 60
Brain Cancer
Breast Cancer		 Dr Jana Portnow City of Hope, Beckman Research Institute Phase 1 Recruiting 39
Brain Cancer Dr Jana Portnow City of Hope, Beckman Research Institute Phase 1 Launching N/A
B cell cancers
Leukemia
Leukemia, Acute Myeloid (AML)		 Dr. Matthew H Porteus Stanford University Phase 1 Recruiting 22
Anemia Dr. Matthew H Porteus Stanford University Phase 1/2 Launching N/A
Heart failure Dr. Matthew Pollman Tenaya Therapeutics, Inc. Phase 1 Launching N/A
Immune Disease
Leukocyte Adhesion Deficiency		 Dr. Kinnari Patel Rocket Pharmaceuticals, Inc. Phase 1/2 Completed 9
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, X-linked (X-SCID)		 Dr. Judith A Shizuru
Wendy Pang		 Stanford University
Jasper Therapeutics, Inc.		 Phase 1/2 Recruiting 40
Brain Cancer Dr. Hideho Okada University of California, San Francisco Phase 1 Launching N/A
Sarcoma Theodore Scott Nowicki University of California, Los Angeles Phase 1 Closed 5
Epilepsy Dr. Cory R Nicholas Neurona Therapeutics Phase 1 Recruiting 40
Epilepsy Dr. Cory R Nicholas Neurona Therapeutics Phase 1/2 Launching N/A
Stroke Dr. Bijan Nejadnik SanBio, Inc. Phase 2 Completed 163
Anemia Ryotaro Nakamura City of Hope, Beckman Research Institute Phase 1 Launching N/A
B cell cancers
Leukemia		 Dr. David B. Miklos Stanford University Phase 1 Active, not recruiting 56
Kidney Failure Dr. Everett H. Meyer Stanford University Phase 1 Recruiting 22
COVID-19 Dr. Michael Matthay MD University of California, San Francisco Phase 2 Completed 120
Heart disease associated with Duchenne muscular dystrophy Dr. Linda Marban Capricor, Inc Phase 2 Completed 25
Alpha Thalassemia Major Dr. Tippi C. MacKenzie University of California, San Francisco Phase 1 Enrolling by invitation 10
Brain Cancer Crystal Mackall Stanford University Phase 1 Recruiting 54
Kidney Failure Dr Robert Lowsky Stanford University Phase 1 Active, not recruiting 15
Pulmonary Hypertension
Vascular Disease		 Dr. Michael I Lewis Cedars-Sinai Medical Center Phase 1/2 Completed 26
Spinal Cord Injury Dr. Jane Stephanie Lebkowski Dr. Geron Corporation Phase 1 Completed 5
Age-related macular degeneration Dr Jane S Lebkowski Regenerative Patch Technologies LLC Phase 2 Launching N/A
Solid Tumors Dr. John Le Gall Allogene Therapeutics Phase 1 Launching N/A
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Active, not recruiting 240
Kidney Failure Jeffrey Lawson Humacyte, Inc. Phase 3 Completed 355
Osteonecrosis Nancy E. Lane University of California, Davis Phase 1/2 Completed 58
Genetic Disorder
Immune Disease
Pediatrics
Severe Combined Immunodeficiency, Adenosine deaminase-deficient (ADA-SCID)		 Dr. Donald B. Kohn
Leslie Meltzer		 University of California, Los Angeles
Orchard Therapeutics plc		 Phase 2 Completed 10
Immune Disease
Pediatrics
X-linked Chronic Granulomatous Disease		 Dr. Donald B. Kohn University of California, Los Angeles Phase 1/2 Recruiting 16
Pediatrics
Sickle Cell Disease		 Dr. Donald B. Kohn University of California, Los Angeles Phase 1 Active, not recruiting 4
Retinitis Pigmentosa Dr. Henry John Klassen University of California, Irvine Phase 1/2 Completed 28
Retinitis Pigmentosa Henry John Klassen jCyte, Inc. Phase 2 Completed 84
Retinitis Pigmentosa Henry John Klassen jCyte, Inc. Phase 2 Completed 84
B cell cancers
Leukemia		 Thomas J Kipps University of California, San Diego Phase 1/2 Active, not recruiting 102
Blood Cancer Thomas J Kipps University of California, San Diego Phase 1 Completed 26
Colon Cancer Ivan King Tachyon Therapeutics, Inc Phase 1 Launching N/A
Neurological Disorders
Other		 Prof. Olivia Kim-McManus University of California, San Diego Phase 1/2 Launching N/A
Amyotrophic Lateral Sclerosis Dr. Ralph Kern BrainStorm Cell Therapeutics Phase 3 Completed 196
Blood Cancer Dr. Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1 Completed 10
Blood Cancer Dr. Edward Kavalerchik Angiocrine Bioscience, Inc. Phase 1/2 Completed 42
Brain Cancer Nori Kasahara University of California, San Francisco Phase 1 Launching N/A
Melanoma Anusha Kalbasi Stanford University Phase 1 Launching N/A
Arthritis
Osteoarthritis		 Dr. Kristen A Johnson Calibr Phase 1 Completed 60
Type 1 diabetes Manasi Jaiman ViaCyte, Inc. Phase 1/2 Completed 49
Age-related macular degeneration Dr. Mark S Humayun University of Southern California Phase 1 Closed 16
Bone or Cartilage Disease
Hearing Loss
Intellectual Disability
Metabolic Disorders
Vision Loss		 Dr Robert Hayes Immusoft Corporation Phase 1 Launching N/A
Brain Cancer Anthony J. Gringeri ImmunoCellular Therapeutics Phase 3 Suspended 234
Immune Disease
Severe Combined Immunodeficiency, X-linked (X-SCID)		 Stephen Gottschalk St. Jude Children’s Research Hospital Phase 1/2 Suspended 28
Type 1 diabetes Howard Foyt ViaCyte, Inc. Phase 1/2 Closed 19
B cell cancers Dr. Paul Finnegan Angiocrine Bioscience, Inc. Phase 3 Closed 130
Developmental Disorders
Spina Bifida		 Dr. Diana L. Farmer University of California, Davis Phase 2 Recruiting 55
Neurological Disorders Amit Etkin Alto Neuroscience Phase 2 Launching N/A
Leukemia, Acute Myeloid (AML) Rochelle Emery Senti Biosciences, Inc. Phase 1 Launching N/A
Lung Cancer Dr. Steven M. Dubinett M.D. University of California, Los Angeles Phase 1 Active, not recruiting 24
HIV/AIDS Mr. Daniel Dornbusch Excision BioTherapeutics Phase 1 Active, not recruiting 6
Melanoma Robert Dillman Caladrius Biosciences Phase 3 Closed 4
Corneal Damage Dr. Sophie X Deng University of California, Los Angeles Phase 1 Recruiting 20
Leukemia, Acute Myeloid (AML) Dr. Colleen Delaney Nohla Therapeutics Inc Phase 2 Closed 146
HIV/AIDS
Immune Disease		 Steven G. Deeks University of California, San Francisco Phase 1/2 Recruiting 18
Severe Combined Immunodeficiency, Artemis deficient (ART-SCID) Mort Cowan University of California, San Francisco Phase 2 Recruiting 25
Solid Tumors Dr. Pamela Reilly Contag PhD BioEclipse Therapeutics INC. Phase 1 Recruiting 60
Beta Thalassemia Bettina Cockroft Sangamo BioSciences, Inc. Phase 1/2 Completed 5
Cystinosis
Kidney Failure		 Dr. Stephanie Cherqui University of California, San Diego Phase 1/2 Active, not recruiting 6
Leukemia, Acute Myeloid (AML) Mark Chao Forty Seven Inc. Phase 1 Closed 258
Colon Cancer Mark Chao Forty Seven Inc. Phase 1/2 Completed 78
Osteoarthritis Dr. Thomas W Chalberg Jr. Genascence Corporation Phase 1 Launching N/A
Sickle Cell Disease Dr Pierre Caudrelier ExCellThera Inc. Phase 1 Withdrawn N/A
HIV/AIDS Dr. Angelo Manuel Almeida Cardoso Ph.D., MD City of Hope, Beckman Research Institute Phase 1 Launching N/A
Leukemia, Acute Myeloid (AML) Elizabeth Budde City of Hope, Beckman Research Institute Phase 1 Launching N/A
Brain Cancer Dr. Christine E. Brown City of Hope, Beckman Research Institute Phase 1 Active, not recruiting 82
Retinitis Pigmentosa Paul Bresge Ray Therapeutics, INC Phase 1 Launching N/A
Kidney Failure Daniel Brennan Medeor Acquisition Corp. Phase 3 Completed 30
Corneal Damage R. Kim Brazzell Combangio, Inc. Phase 2 Launching N/A
Spinal Cord Injury Francois Binette Lineage Cell Therapeutics, Inc. Phase 1/2 Completed 25
Anemia
Bone Marrow Transplant and Viral Infection		 Alice Bertaina Stanford University Phase 1/2 Launching N/A
Immune Disease DR Jonathan Benjamin ImmPACT-Bio, Inc. Phase 1/2 Launching N/A
Multiple Myeloma Rajesh Belani MD Poseida Therapeutics, Inc. Phase 1 Closed 105
Muscle Injury Peter C Belafsky University of California, Davis Phase 1/2 Recruiting 62
Parkinson's Disease Krystof S. Bankiewicz Brain Neurotherapy Bio Phase 1 Active, not recruiting 11
IPEX Syndrome Dr. Rosa Bacchetta Stanford University Phase 1 Recruiting 30
HIV-related Lymphoma
HIV/AIDS		 Dr Mehrdad Abedi University of California, Davis Phase 1/2 Active, not recruiting 11